anti-mouse cd40l clone mr-1  (Bio X Cell)

Journal: The Journal of Clinical Investigation

Article Title: CXCL12 + fibroblastic reticular cells in lymph nodes facilitate immune tolerance by regulating T cell–mediated alloimmunity

doi: 10.1172/JCI182709

Figure Lengend Snippet: ( A ) Comparison of heart allograft survival among WT C57BL/6J, Ccl19 Cre Ltbr fl/fl , and Ccl19 Cre Ltbr fl/fl recipients with FRC injections ( n = 7–9 mice/group). Graft survival data were combined from 3 independent experiments. ( B ) Representative images and comparison of CD3-, CD11b-, and collagen 1–stained heart allografts from WT C57BL/6J and Ccl19 Cre Ltbr fl/fl recipients ( n = 4 mice/group). Scale bars: 200 μm. ( C ) Flow cytometry analysis of DLNs from WT C57BL/6J and Ccl19 Cre Ltbr fl/fl recipients ( n = 4 mice/group). ( D ) Representative images and comparison of Foxp3-stained DLNs ( n = 4 mice/group). Scale bars: 200 μm. ( E ) Flow cytometry analysis of transferred TCR Tg cells in DLNs ( n = 4 mice/group). ( F ) Comparison of heart allograft survival among WT C57BL/6J recipients treated with anti-LTβR agonist mAb alone (20 μg i.v. on day 0), anti-CD40L alone (40 μg i.v. on day 0), and both anti-LTβR agonist mAb and anti-CD40L of BALB/c hearts ( n = 6 mice/group). Graft survival data were combined from 2 independent experiments. log-rank test for graft survival. Student’s t test for comparisons between 2 groups. Data are represented as means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: As the standard protocol in this study, anti-CD40L mAb (MR1, 125 μg i.v. on days 0 and 1, BioXCell, BE0017-1) or CTLA4-Ig (Abatacept, 500 μg i.p. on day 0 and 250 μg i.p. on days 2, 4, 6, 8, Bristol-Myers Squibb) was administered to recipient mice.

Techniques: Comparison, Staining, Flow Cytometry

Journal: The Journal of Clinical Investigation

Article Title: CXCL12 + fibroblastic reticular cells in lymph nodes facilitate immune tolerance by regulating T cell–mediated alloimmunity

doi: 10.1172/JCI182709

Figure Lengend Snippet: ( A ) Unsupervised clustering of FRC subset clusters visualized with UMAP in LNSCs from naive LNs. ( B ) Violin plots of Ltbr and Cxcl12 expression among FRC subset clusters in naive LNs. ( C ) Violin plots of Ltbr and Cxcl12 expression in total FRCs from naive LNs. ( D ) UMAP of SC populations in naive LNs and DLNs, highlighting Cxcl12 expression on MedRC, TRC, and PRC subsets. ( E ) Violin plots of Cxcl12 expression in FRC subsets from naive LNs and DLNs. ( F ) Volcano plot comparing CXCL12 hi and CXCL12 lo FRCs in mouse LNSCs from heart transplanted recipients with anti-CD40L treatment. ( G ) Top 20 overrepresented ontology pathways based on DEGs in mouse LNSCs. ( H ) Volcano plot comparing CXCL12 hi and CXCL12 lo FRCs in human LNSCs. ( I ) Top 20 overrepresented ontology pathways in human LNSCs. Common genes shared between mouse and human are highlighted with bold letters surrounded by squares ( F and H ). Ontology pathways related to chemotaxis and migration are highlighted with bold letters surrounded by squares ( G and I ). HTx, heart transplantation.

Article Snippet: As the standard protocol in this study, anti-CD40L mAb (MR1, 125 μg i.v. on days 0 and 1, BioXCell, BE0017-1) or CTLA4-Ig (Abatacept, 500 μg i.p. on day 0 and 250 μg i.p. on days 2, 4, 6, 8, Bristol-Myers Squibb) was administered to recipient mice.

Techniques: Expressing, Chemotaxis Assay, Migration, Transplantation Assay

Journal: STAR Protocols

Article Title: Protocol for renal subcapsular islet transplantation in diabetic mice to induce long-term immune tolerance

doi: 10.1016/j.xpro.2025.103729

Figure Lengend Snippet: Dual antibody treatment regimens post-transplant (A) Anti-CD45RB combined with anti-TIM1 treatment protocol. (B) Anti-CD45RB combined with anti-CD40L treatment protocol.

Article Snippet: InVivoMAb anti-mouse CD40L (CD154) (diluted 1:2) , Bio X Cell , CAT#BE0017; RRID: AB_1107601.

Techniques:

Journal: STAR Protocols

Article Title: Protocol for renal subcapsular islet transplantation in diabetic mice to induce long-term immune tolerance

doi: 10.1016/j.xpro.2025.103729

Figure Lengend Snippet:

Article Snippet: InVivoMAb anti-mouse CD40L (CD154) (diluted 1:2) , Bio X Cell , CAT#BE0017; RRID: AB_1107601.

Techniques: Recombinant, Cell Culture, Transferring, Microscopy, Stripping Membranes, Flow Cytometry